Rps Research Iberica
Rps Research Iberica is recorded as a service provider in 22 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 22 trials · Latest update first
An open-label, multi-center, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 in participants with severe, refractory systemic lupus erythematosus (srSLE).
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A phase Ib/II, multicenter study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancer
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren’s syndrome (NEPTUNUS-2)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT - physician’s choice in the treatment of newly diagnosed RMS (STHENOS)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available3 trial-level findings · Read insights
- The trial enrolled 185 participants at 41 centres across Germany, France, Italy, and Spain.
- A 2022 protocol amendment enlarged the eligible population, reduced protocol complexity, and revised eligibility criteria to align with current ofatumumab and other DMT product information.
- A 2021 protocol amendment required full routine laboratory testing at every on-site visit from baseline through Month 15.
These findings describe the trial, not the service provider’s performance or responsibility.
PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A two-year, double-blind, randomized, multicenter, active-controlled Core Phase study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly in pediatric patients with multiple sclerosis with five-year fingolimod Extension Phase
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, subject and investigator blinded, placebo controlled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
EPIK-P3: A phase II study to evaluate the long-term safety and efficacy of alpelisib in patients with PIK3CA Related-Overgrowth Spectrum (PROS) who previously participated in Study CBYL719F12002 (EPIK-P1)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A three-period multicenter study, with a randomized-withdrawal, double-blinded, placebo-controlled design to evaluate the clinical efficacy, safety and tolerability of MAS825 in patients with monogenic IL-18 driven autoinflammatory diseases, including NLRC4-GOF, XIAP deficiency, or CDC42 mutations.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open label, multicenter roll-over extension program (REP) to characterize the long-term safety and tolerability of iptacopan (LNP023) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have completed PNH Phase 2 and Phase 3 studies with iptacopan.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase II, single arm, multicenter open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An Open-label, Multi-center, Phase IV, Rollover Study for Patients with Sickle Cell Disease who have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo controlled, 2-armmulticenter phase 3 study to assess the efficacy and safetyof ianalumab in patients with active Sjögren’s syndrome(NEPTUNUS-1)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises (STAND)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A 5- year randomized, double-blind, placebo-controlled, multi-center study assessing the efficacy, safety, and tolerability of intra-articular regimens of LNA043 versus placebo in patients with symptomatic knee osteoarthritis (ONWARDS)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, two-arm, placebo-controlled, participant, investigator and sponsor-blinded, proof-of-concept study investigating the efficacy, safety and tolerability of QUC398 in patients with symptomatic knee osteoarthritis
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Rps Research Iberica?
The 2026-10-09 snapshot links Rps Research Iberica to 22 distinct CTIS trials. Recorded services include Clinical monitoring. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Rps Research Iberica?
The most frequently recorded therapeutic areas are Immunology, Neurology, Rheumatology, Solid Tumor Oncology. Recorded phases include Phase 3, Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Rps Research Iberica conducted?
The linked trials record locations in 23 countries, including Spain, France, Germany, Belgium, Czechia. These are trial locations, not confirmed office locations or countries where Rps Research Iberica delivered services.
What can this page tell me about Rps Research Iberica's trial experience?
Browse 22 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Rps Research Iberica. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Rps Research Iberica S.L.